Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05565313 | Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI(AI4rENE) | active not recruiting | — | 900 | Maastricht Radiation OncologyOTHER | 3 | Aug 14, 2025 | clinicaltrials |
| NCT06177301 | Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC | recruiting | Phase 3 | 266 | Fudan UniversityOTHER | 1 | Aug 14, 2025 |
| NCT06492460 | 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma | recruiting | Phase 3 | 422 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06700070 | A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors | recruiting | Early Phase 1 | 12 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05222932 | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1(AVENTIL) | active not recruiting | Phase 1 | 15 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT07110558 | Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma(PUPA) | not yet recruiting | Phase 2 | 59 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07105592 | A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 68 | Fudan UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04675333 | Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) | active not recruiting | Phase 2 | 172 | ALX Oncology Inc.INDUSTRY | 8 | Aug 3, 2025 | clinicaltrials |
| NCT07072325 | Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers | not yet recruiting | Phase 1 | 9 | West China HospitalOTHER | 0 | Aug 3, 2025 | clinicaltrials |
| NCT04675294 | Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | active not recruiting | Phase 2 | 189 | ALX Oncology Inc.INDUSTRY | 9 | Aug 1, 2025 | clinicaltrials |
| NCT03649048 | Low-Dose Weekly vs High-Dose Cisplatin(RADIO) | recruiting | N/A | 100 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06307015 | De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)(DE-RADIATE) | recruiting | N/A | 25 | Royal North Shore HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06236464 | Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas | recruiting | — | 170 | National Cancer Institute, NaplesOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06805617 | A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers(I-MAC) | recruiting | Phase 2 | 35 | Glenn J. HannaOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07090707 | PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006) | not yet recruiting | Phase 2 | 50 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07088484 | Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | — | 50 | Fujian Cancer HospitalOTHER_GOV | 0 | Jul 28, 2025 | clinicaltrials |
| NCT07085234 | Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085988 | Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 109 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05540899 | Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer | active not recruiting | Phase 1 | 14 | American College of RadiologyOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07079410 | Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06935188 | Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC | recruiting | Phase 2 | 98 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072000 | Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity | not yet recruiting | Phase 3 | 550 | Hai-Qiang Mai,MD,PhDOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072676 | The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.(Risk of fall) | enrolling by invitation | N/A | 30 | LMU KlinikumOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT05774483 | Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative(SECOND N0) | recruiting | N/A | 508 | Tata Memorial HospitalOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04907370 | PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma(DIAMOND) | active not recruiting | Phase 3 | 532 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07067268 | Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy | recruiting | Phase 2 | 76 | Fudan UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05147844 | Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 40 | Xinqiao Hospital of ChongqingOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07062211 | Diagnostic Accuracy of Fluorodeoxyglucose-18 PET in the Evaluation of RPTC With Patient's Raised Thyroglobulin Level | active not recruiting | — | 39 | Superior UniversityOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07058116 | Accelerator-based BNCT (Boron Neutron Capture Therapy) for Head and Neck Carcinoma.(BNCT) | recruiting | Phase 1 | 10 | Neutron Therapeutics, LLCINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07055841 | Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 69 | Xiuping DingOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06228079 | Adjuvant vs Surgery Only in Early-stage Recurrent NPC | recruiting | Phase 3 | 176 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT07048964 | A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations | not yet recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 3, 2025 | clinicaltrials |
| NCT05272696 | Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC | recruiting | Phase 2 | 86 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06676722 | SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy | recruiting | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07042711 | Impact of Vitamin D on Therapeutic Respons in NPC Chemoradiated Patients | active not recruiting | N/A | 300 | Indonesia UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07042984 | RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer(RET-US) | not yet recruiting | — | 800 | Fujian Medical UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07036185 | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors | not yet recruiting | Phase 1 | 66 | Shanghai Bao Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036211 | Transmission of Oncogenic HPV Infection Among Families(TREVINO) | not yet recruiting | — | 700 | Tampere University HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06061705 | Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies(iMonitORL) | recruiting | N/A | 100 | Fondation Hôpital Saint-JosephOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT04305795 | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 23 | Rakuten Medical, Inc.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT07028918 | A Prospective Single-Arm Study（NCLDR）(NCLDR) | not yet recruiting | Early Phase 1 | 35 | Qilu Hospital of Shandong UniversityOTHER | 0 | Jun 19, 2025 | clinicaltrials |
| NCT03341936 | Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN | active not recruiting | Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07019870 | Screening for Early Diagnosis of Nose Cancer | recruiting | N/A | 20,000 | National University Hospital, SingaporeOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04946968 | Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers | active not recruiting | Phase 2 | 24 | National Cancer Centre, SingaporeOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07011329 | Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.(NPC) | active not recruiting | — | 60 | Hubei Cancer HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03854032 | Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | active not recruiting | Phase 2 | 45 | Thomas Jefferson UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2025source: clinicaltrials